Skip to main content

Burgeoning Chronic Diseases to Proliferate the Advanced Drug Delivery Market

Home » Press Release » Burgeoning Chronic Diseases to Proliferate the Advanced Drug Delivery Market

May 17, 2022

Burgeoning Chronic Diseases to Proliferate the Advanced Drug Delivery Market

The advanced drug delivery market is expected to expand at a CAGR of 16.0%, reaching the estimated value of USD 1,95,132.45mn between 2020 to 2030.

Researchmoz elucidates the market dynamics of the advanced drug delivery market including market size, growth drivers, restraints, trends, opportunities, segment dominance, and competitive edge.

The burgeoning chronic diseases are expected to strengthen the market during the forecast period.

Factors Driving and Restraining the Market

Some of the determinants of the growth of the advanced drug delivery market include-

The advanced technology in the drug delivery system is expected to drive the market towards significant growth.

For instance- West Pharmaceuticals getting into an agreement with Corning Incorporated for advanced technology for an advanced injectable drug delivery system to offer better safety for patients

Benefits such as target-oriented therapy, reduced dosing frequency, lower toxicity, and increased efficacy are anticipated to bolster the market significantly during the forecast period.

Rising investment in research and development in biotechnology and genetic engineering is expected to boost the demand for advanced drug delivery in the forthcoming years.

The controlled dosing system provides better patient compliance, and easy treatment methods, owing to the market expansion of advanced drug delivery during the forecast period.

The rapid development in nanotechnology and the development of nanoparticles to overcome the barriers of conventional methods of drug delivery are expected to drive the expansion of the market in the following years.

There are various factors that are expected to stimulate the growth opportunities in the global advanced drug delivery market, however, there are a couple of challenges that may restrain the growth.

The high cost of drug development, lack of infrastructure for research and development, and stringent regulations may hinder the growth of the global advanced drug delivery market during the forecast period.

Nevertheless, the advanced drug development is expected to grow, owing to recent advancements in genomics (gene-based targeted therapy) and the development of new biopharmaceuticals.

Analyst’s Overview

 The global advanced drug delivery market is expected to grow exponentially at a noteworthy CAGR of 16.0% between 2020 to 20230, marking up to the estimated value of USD 1,95,132.45mn.

The first drug delivery system originated in 1855, in the form of syringes, however, it is since 1970 that the advent of the drug delivery system started gaining traction, now paving way for advanced drug delivery systems with next-generation drug delivery technologies.

The development of nanoparticles aims at the controlled release of drugs offering therapeutic efficacy and lower toxicity to meet the unmet needs in healthcare facilities.

The sudden rise in the number of chronic diseases in the recent past has crowded the hospital sector with inpatients and outpatients visits, thus fuelling the growth in the advanced drug delivery market.

The Asia Pacific followed by North America and Europe is expected to hold its dominance over the advanced drug delivery market, owing to increased expenditure on research and development, a number of chronic diseases, medical tourism, availability of advanced technology, and better healthcare infrastructure respectively.

Competitive Landscape

The global advanced drug delivery market players are expected to invest their focus and funds on strategies such as collaborations, acquisitions, and new product launches.

Some of the existing key players of the advanced drug delivery market are –

  • Alnylam Pharmaceuticals Inc.
  • Endo International Plc.
  • Biogen Limited
  • Micropoint Technologies
  • Bausch Health Companies Inc. (Bausch & Lomb)
  • Altaris Capital Partners Llc. (Kindeva Drug Delivery)
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited.
  • Johnson & Johnson (Johnson & Johnson Vision)
  • Ocular Therapeutix Inc.

Key Takeaways

The development of smart drug delivery is quintessential for intelligently targeted therapeutics.

Groundbreaking approaches and strategies such as nanotechnology is expected to advance the treatment approaches and drug performances.

The controlled oral delivery system is expected to gain traction in the advanced drug delivery market due to being less expensive, easy to administer, and less painful as compared to other modes of drug delivery.

The market is moderately competitive; however, it is quite challenging to penetrate the market unless there is intensive research not just about the drugs but also about the possibilities of drug recalls and failures and their impacts.

Product/Type Disposition (Revenue in USD million)

  • Oral Drug Delivery System
  • Injection based Drug Delivery System
  • Inhalation/ Pulmonary Drug Delivery System
  • Transdermal Drug Delivery System
  • Parenteral Drug Delivery System

Application Disposition (Revenue in USD million)

  • Liposomes
  • Nano Particles
  • Microspheres
  • Monoclonal Antibodies
  • Others
  • End Users Dispositions (Revenue in USD million)
  • Hospitals
  • Specialized Clinics
  • Clinical Research & Development Centres

Regional Disposition

  • North America
    • U.S.
    • Canada
  • Europe
    • UK.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa (MEA)

Media Contact

Please drop a mail to the Global PR Team for your queries

Contact Us

We Are Just A Click Away!

[email protected]